Adding Value to Liver (and Allograft) Biopsy Evaluation Using a Combination of Multiplex Quantum Dot Immunostaining, High-Resolution Whole-Slide Digital Imaging, and Automated Image Analysis

Clinics in Liver Disease

Volumn 14, Issue 4, 2010, Pages 669-685

  Isse, Kumiko ^a   Grama, Kedar ^b   Abbott, Isaac Morse ^b   Lesniak, Andrew ^a   Lunz, John G ^a   Lee, William M F ^c   Specht, Susan ^a   Corbitt, Natasha ^a   Mizuguchi, Yoshiaki ^a   Roysam, Badrinath ^b   Demetris, A J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Houston   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Automated image analysis; Digital pathology; Liver allograft pathology; Liver biopsy; Multiplex immunostaining

Indexed keywords

ANTIGEN BINDING; AUTOMATED IMAGE ANALYSIS; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURVIVAL; CHRONIC HEPATITIS; DIGITAL IMAGING; ENDOTHELIUM; HIGH RESOLUTION WHOLE SLIDE DIGITAL IMAGING; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER GRAFT; MICROSCOPY; MULTIPLEX QUANTUM DOT IMMUNOSTAINING; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; STAINING; STELLATE CELL;

AUTOMATIC DATA PROCESSING; BIOPSY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LIVER DISEASES; QUANTUM DOTS;

EID: 78049461402     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.07.004     Document Type: Review

References (63)

1. Mells G., Mann C., Hubscher S., et al. Late protocol liver biopsies in the liver allograft: a neglected investigation?. Liver Transpl 2009, 15:931-938.
2. Mells G., Neuberger J. Protocol liver allograft biopsies. Transplantation 2008, 85:1686-1692.
3. Muthukumar T., Dadhania D., Ding R., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005, 353:2342-2351.
4. Dinu I., Potter J.D., Mueller T., et al. Gene-set analysis and reduction. Brief Bioinform 2009, 10:24-34.
5. Bunnag S., Einecke G., Reeve J., et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009, 20:1149-1160.
6. Martinez-Llordella M., Lozano J.J., Puig-Pey I., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118:2845-2857.
7. Martinez-Llordella M., Puig-Pey I., Orlando G., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007, 7:309-319.
8. Rush D. Can protocol biopsy better inform our choices in renal transplantation?. Transplant Proc 2009, 41:S6-S8.
9. Schaub S., Nickerson P., Rush D., et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009, 9:1347-1353.
10. Schaub S., Mayr M., Honger G., et al. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation 2007, 84:104-112.
11. Louvar D.W., Li N., Snyder J., et al. " Nature versus nurture" study of deceased-donor pairs in kidney transplantation. J Am Soc Nephrol 2009, 20:1351-1358.
12. Kamoun M., Holmes J.H., Israni A.K., et al. HLA-A amino acid polymorphism and delayed kidney allograft function. Proc Natl Acad Sci U S A 2008, 105:18883-18888.
13. Israni A.K., Li N., Cizman B.B., et al. Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function after kidney transplantation. Am J Kidney Dis 2008, 52:331-339.
14. Ishak K., Baptista A., Bianchi L., et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
15. Batts K.P., Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995, 19:1409-1417.
16. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
17. Demetris A.J., Ruppert K., Dvorchik I., et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002, 74:1290-1296.
18. Demetris A., Adams D., Bellamy C., et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000, 31:792-799.
19. Nakanuma Y., Zen Y. Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatol Res 2007, 37(Suppl 3):S478-S486.
20. Bioulac-Sage P., Laumonier H., Rullier A., et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 2009, 29:459-465.
21. Di Tommaso L., Destro A., Seok J.Y., et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009, 50:746-754.
22. Kakar S., Gown A.M., Goodman Z.D., et al. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007, 131:1648-1654.
23. Bioulac-Sage P., Rebouissou S., Thomas C., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748.
24. Wang L., Vuolo M., Suhrland M.J., et al. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 2006, 50:257-262.
25. Morrison C., Marsh W., Frankel W.L. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 2002, 15:1279-1287.
26. Minervini M.I., Demetris A.J., Lee R.G., et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997, 10:686-692.
27. Kirimlioglu H., Dvorchick I., Ruppert K., et al. Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology 2001, 34:502-510.
28. Banff Working G., Demetris A.J., Adeyi O., et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006, 44:489-501.
29. Therneau T. The perils and promise of high-dimensional biology. Hepatology 2009, 49:1061-1062.
30. Wu T., Cieply K., Nalesnik M.A., et al. Minimal evidence of transdifferentiation from recipient bone marrow to parenchymal cells in regenerating and long-surviving human allografts. Am J Transplant 2003, 3:1173-1181.
31. van der Loos C.M., Becker A.E., van den Oord J.J. Practical suggestions for successful immunoenzyme double-staining experiments. Histochem J 1993, 25:1-13.
32. McCaughan G.W., Davies J.S., Waugh J.A., et al. A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: the use of monoclonal antibodies and double immunolabeling. Hepatology 1990, 12:1305-1313.
33. Krenacs T., Krenacs L., Bozoky B., et al. Double and triple immunocytochemical labelling at the light microscope level in histopathology. Histochem J 1990, 22:530-536.
34. Waiser J., Schwaar S., Bohler T., et al. Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols. Virchows Arch 2002, 440:648-654.
35. Wang M., Xue L., Cao Q., et al. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 2009, 56:533-541.
36. Yang J.C., Teng C.F., Wu H.C., et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009, 49:1962-1971.
37. Suzuki S., Takeshita K., Asamoto M., et al. High mobility group box associated with cell proliferation appears to play an important role in hepatocellular carcinogenesis in rats and humans. Toxicology 2009, 255:160-170.
38. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41:5-15.
39. Demetris A.J., Lunz J.G., Randhawa P., et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009, 22:120-141.
40. Evans H.M., Kelly D.A., McKiernan P.J., et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006, 43:1109-1117.
41. Wong T., Nouri-Aria K.T., Devlin J., et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998, 28:443-449.
42. Yoshitomi M., Koshiba T., Haga H., et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009, 87:606-614.
43. Xu Q., Lee J., Jankowska-Gan E., et al. Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol 2007, 178:3983-3995.
44. Kang S.M., Tang Q., Bluestone J.A. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007, 7:1457-1463.
45. Shen-Orr S.S., Tibshirani R., Khatri P., et al. Cell type-specific gene expression differences in complex tissues. Nat Methods 2010, 7(4):287-289.
46. Tholouli E., Sweeney E., Barrow E., et al. Quantum dots light up pathology. J Pathol 2008, 216:275-285.
47. Sweeney E., Ward T.H., Gray N., et al. Quantitative multiplexed quantum dot immunohistochemistry. Biochem Biophys Res Commun 2008, 374:181-186.
48. Fountaine T.J., Wincovitch S.M., Geho D.H., et al. Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Mod Pathol 2006, 19:1181-1191.
49. Bjornsson C.S., Lin G., Al-Kofahi Y., et al. Associative image analysis: a method for automated quantification of 3D multi-parameter images of brain tissue. J Neurosci Methods 2008, 170:165-178.
50. Isse K., Lunz Iii J.G., Specht M.S., et al. Combining H&E, multiplex quantum dot immunostaining, and whole slide imaging for liver biopsy evaluation. Hepatology 2009, 50(Suppl). [abstract 1234].
51. Isse K., Specht S.M., Lunz J.G., et al. Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice and humans. Hepatology 2009, 51:869-880.
52. Toso C., Isse K., Demetris A.J., et al. Histologic graft assessment after clinical islet transplantation. Transplantation 2009, 88:1286-1293.
53. Koshiba T., Li Y., Takemura M., et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007, 17:94-97.
54. Al-Kofahi Y., Lassoued W., Lee W., et al. Improved automatic detection and segmentation of cell nuclei in histopathology images. IEEE Trans Biomed Eng 2009, 57(4):841-852.
55. Lepin E.J., Zhang Q., Zhang X., et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006, 6:1560-1571.
56. Weinstein R.S., Graham A.R., Richter L.C., et al. Overview of telepathology, virtual microscopy, and whole slide imaging: prospects for the future. Hum Pathol 2009, 40:1057-1069.
57. Rocha R., Vassallo J., Soares F., et al. Digital slides: present status of a tool for consultation, teaching, and quality control in pathology. Pathol Res Pract 2009, 205:735-741.
58. Pinco J., Goulart R.A., Otis C.N., et al. Impact of digital image manipulation in cytology. Arch Pathol Lab Med 2009, 133:57-61.
59. Coleman R. Can histology and pathology be taught without microscopes? The advantages and disadvantages of virtual histology. Acta Histochem 2009, 111:1-4.
60. Montalto M.C., Cartwright G. From the incandescent light bulb to digital pathology: corporate innovation as an engine for change. Arch Pathol Lab Med 2009, 133:550-552.
61. Minot D.M., Kipp B.R., Root R.M., et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH. Am J Clin Pathol 2009, 132:133-138.
62. Gustavson M.D., Bourke-Martin B., Reilly D., et al. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 2009, 133:1413-1419.
63. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056.